This compound serves as a critical chiral intermediate in the synthesis of Clopidogrel, a widely used antiplatelet agent and active pharmaceutical ingredient (API). Clopidogrel is primarily employed in the prevention of thrombotic events in patients with cardiovascular conditions, such as acute coronary syndrome, myocardial infarction, and ischemic stroke. Its specific stereochemistry, as indicated by the (S) configuration, is essential for the biological activity of the final drug, which inhibits platelet aggregation by antagonizing the P2Y12 receptor. This intermediate enables efficient and stereoselective synthesis routes in pharmaceutical production, contributing to the development of effective antithrombotic therapies with improved safety profiles.